DK166479C - Anvendelse af fluoxetin, norfluoxetin eller et farmaceutisk acceptabelt salt af fluoxetin eller norfluoxetin til fremstilling af et laegemiddel med anxiolytisk virkning - Google Patents

Anvendelse af fluoxetin, norfluoxetin eller et farmaceutisk acceptabelt salt af fluoxetin eller norfluoxetin til fremstilling af et laegemiddel med anxiolytisk virkning

Info

Publication number
DK166479C
DK166479C DK113284A DK113284A DK166479C DK 166479 C DK166479 C DK 166479C DK 113284 A DK113284 A DK 113284A DK 113284 A DK113284 A DK 113284A DK 166479 C DK166479 C DK 166479C
Authority
DK
Denmark
Prior art keywords
norfluoxetin
fluoxetin
anxiolytical
medicine
preparation
Prior art date
Application number
DK113284A
Other languages
Danish (da)
English (en)
Other versions
DK166479B (da
DK113284D0 (da
DK113284A (da
Inventor
Paul Stark
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK113284D0 publication Critical patent/DK113284D0/da
Publication of DK113284A publication Critical patent/DK113284A/da
Publication of DK166479B publication Critical patent/DK166479B/da
Application granted granted Critical
Publication of DK166479C publication Critical patent/DK166479C/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
DK113284A 1983-04-08 1984-02-28 Anvendelse af fluoxetin, norfluoxetin eller et farmaceutisk acceptabelt salt af fluoxetin eller norfluoxetin til fremstilling af et laegemiddel med anxiolytisk virkning DK166479C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/483,087 US4590213A (en) 1983-04-08 1983-04-08 Anti-anxiety method
US48308783 1983-04-08

Publications (4)

Publication Number Publication Date
DK113284D0 DK113284D0 (da) 1984-02-28
DK113284A DK113284A (da) 1984-10-09
DK166479B DK166479B (da) 1993-06-01
DK166479C true DK166479C (da) 1993-10-18

Family

ID=23918597

Family Applications (1)

Application Number Title Priority Date Filing Date
DK113284A DK166479C (da) 1983-04-08 1984-02-28 Anvendelse af fluoxetin, norfluoxetin eller et farmaceutisk acceptabelt salt af fluoxetin eller norfluoxetin til fremstilling af et laegemiddel med anxiolytisk virkning

Country Status (9)

Country Link
US (1) US4590213A (ja)
EP (1) EP0123469B1 (ja)
JP (1) JPH0635382B2 (ja)
AU (1) AU556476B2 (ja)
DE (2) DE3413093A1 (ja)
DK (1) DK166479C (ja)
GB (1) GB2137496B (ja)
IT (1) IT1175977B (ja)
ZA (1) ZA842457B (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824868A (en) * 1982-09-07 1989-04-25 Ciba-Geigy Corporation Propylamine derivatives useful for the treatment of dementia
ES2058272T3 (es) * 1987-05-04 1994-11-01 Lilly Co Eli Fluoxetina util para el tratamiento de la diabetes.
JP2938463B2 (ja) * 1987-10-22 1999-08-23 マサチユセツツ・インスチチユート・オブ・テクノロジー 月経前又は後期黄体期症候群の処置
US5223540A (en) * 1987-10-22 1993-06-29 Massachusetts Institute Of Technology Method for treating the premenstrual or late luteal phase syndrome
US4971998A (en) * 1987-10-22 1990-11-20 Massachusetts Institute Of Technology Methods for treating the premenstrual or late luteal phase syndrome
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
PT98628A (pt) * 1990-08-09 1992-06-30 Massachusetts Inst Technology Processo de composicoes farmaceuticas a base de por exemplo sertralina
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5830500A (en) * 1996-07-22 1998-11-03 Pentech Pharmaceuticals, Inc. Low dose fluoxetine tablet
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
ES2237188T3 (es) * 1998-11-23 2005-07-16 Sepracor Inc. Composiciones de desmetilolanzapina y metodos.
US7034059B2 (en) * 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
WO2003014114A2 (en) * 2001-08-08 2003-02-20 Neurosearch A/S Substituted amine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
JP5299430B2 (ja) * 2008-09-30 2013-09-25 アイシン・エィ・ダブリュ株式会社 自動変速機
EA201590044A1 (ru) 2012-07-31 2015-09-30 Сановел Хайван Саглиги Юрюнлери Санайи Ве Тиджарет А.С. Применение флуоксетина у животных
US20150174083A1 (en) 2012-07-31 2015-06-25 Sanovel Hayvan Sagligi Urunleri Sanayi Ve Ticaret Anonim Sirketi Use of fluoxetine for increasing meat and milk production

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4313896A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Aryloxyphenylpropylamines
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4329356A (en) * 1980-10-31 1982-05-11 Eli Lilly And Company Treatment of hypertension with fluoxetine and l-5-hydroxytryptophane

Also Published As

Publication number Publication date
IT8420432A0 (it) 1984-04-06
EP0123469A1 (en) 1984-10-31
AU2645784A (en) 1984-10-11
GB2137496B (en) 1986-10-01
DE3413093A1 (de) 1984-10-11
DK166479B (da) 1993-06-01
AU556476B2 (en) 1986-11-06
JPH0635382B2 (ja) 1994-05-11
ZA842457B (en) 1985-11-27
IT8420432A1 (it) 1985-10-06
GB2137496A (en) 1984-10-10
DK113284D0 (da) 1984-02-28
DK113284A (da) 1984-10-09
GB8408880D0 (en) 1984-05-16
IT1175977B (it) 1987-08-12
JPS59193821A (ja) 1984-11-02
DE3467704D1 (en) 1988-01-07
US4590213A (en) 1986-05-20
EP0123469B1 (en) 1987-11-25

Similar Documents

Publication Publication Date Title
DK253988A (da) Farmaceutisk praeparat med indhold af eperison eller tolperison, eller et salt deraf, til indgivelse gennem huden
DK166479C (da) Anvendelse af fluoxetin, norfluoxetin eller et farmaceutisk acceptabelt salt af fluoxetin eller norfluoxetin til fremstilling af et laegemiddel med anxiolytisk virkning
DK156376C (da) Anvendelse af ibogain til fremstilling af et laegemiddel til behandling af narkotikamisbrug
DK146482A (da) Fremgangsmaade til fremstilling af cyklobutylaminderivater eller farmaceutisk acceptable salte deraf
DK74282A (da) Fremgangsmaade til fremstilling af imidazodiazepiner eller farmaceutisk acceptable syreadditionssalte deraf
IT8267184A0 (it) Bendaggio per la somministrazione di medicamenti
DK152114C (da) Analogifremgangsmaade til fremstilling af propenylaminer eller farmaceutisk acceptable salte deraf
DK161968C (da) Analogifremgangsmaade til fremstilling af imidazo-pyrazolo-pyrimidiner eller farmaceutisk acceptable salte deraf
DK163181C (da) Analogifremgangsmaade til fremstilling af n,n'-di(arylalkylen)alkylendiaminer eller farmaceutisk acceptable salte deraf
DK645788D0 (da) Anvendelse af ergolinderivater til fremstilling af et farmaceutisk praeparat
NO157506C (no) Fremgangsmaate for fremstilling av human-insulin eller treoninb30-derivater av human-insulin eller et salt eller kompleks derav.
DK158658C (da) Analogifremgangsmaade til fremstilling af 9-aminoalkylfluorener eller farmaceutisk acceptable salte deraf
DK151805C (da) Analogifremgangsmaade til fremstilling af 20,21-di-nor-eburnameninderivater eller farmaceutisk acceptable additionssalte deraf
DK321482A (da) Fremgangsmaade til fremstilling af 1-imidazolyl-2-phenyl-8-piperazinylphenoxy-octan-2-ol-forbindelser eller farmaceutisk acceptable syreadditionssalte deraf
DK232777A (da) Fremgangsmade til fremstilling af imidazothiaziner eller farmaceutisk acceptable salte deraf
DK386783D0 (da) Fremgangsmade til fremstilling af benzamidderivater eller et farmaceutisk acceptabelt salt deraf
DK15282A (da) Fremgangsmaade til fremstilling af (+)-enantiomere eller (+)(-)-racemiske 4a,9b-trans-hexahydro-1h-pyridoindol-derivater eller farmaceutisk acceptable syreadditionssalte deraf
DK473088D0 (da) Anvendelse af 2-amino-6-trifluormethoxybenzothiazol til fremstilling af et laegemiddel
DK473288A (da) Anvendelse af 2-amino-6-trifluormethoxybenzothiazol til fremstilling af et laegemiddel
DK232877A (da) Fremgangsmade til fremstilling af 2-imino-3-aminothiazolidiner eller farmaceutisk acceptable salte deraf
DK149823C (da) Fremgangsmaade til fremstilling af kijanimicin eller farmaceutisk acceptable salte heraf
DK586284D0 (da) Quinoloncarboxylsyre-derivater, fremgangsmaade til fremstilling deraf samt anvendelse af saadanne derivater som laegemiddel
DK150521C (da) Analogifremgangsmaade til fremstilling af n2-arylsulfonyl-l-argininamider eller farmaceutisk acceptable salte deraf
DK302887A (da) Anvendelse af tumornecrosefaktor-alfa til fremstilling af antiinfektivt laegemiddel
ES529565A0 (es) Procedimiento de preparacion de eteres oximas basicos, y de sus sales de adicion acidas farmaceuticamente aceptables